Exact Sciences Stock News

Equities research analysts expect Exact Sciences Co. (NASDAQ:EXAS) to report sales of $441.89 million for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have made estimates for Exact Sciences earnings. The highest sales estimate is $457.30 million and the lowest is $436.70 million. Exact Sciences posted sales of $466.34 million in the []

IFG Advisory LLC grew its holdings in Exact Sciences Co. (NASDAQ:EXAS) by 17.2% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 30,434 shares of the medical research companys stock after purchasing an additional 4,466 shares during the period. IFG Advisory LLCs []

Exact Sciences Co. (NASDAQ:EXAS)s share price reached a new 52-week low during trading on Thursday . The company traded as low as $85.61 and last traded at $86.38, with a volume of 29171 shares changing hands. The stock had previously closed at $88.38. A number of analysts have recently commented on the company. Oppenheimer cut []

Golden Green Inc. decreased its stake in Exact Sciences Co. (NASDAQ:EXAS) by 8.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,159 shares of the medical research companys stock after selling 499 shares during the quarter. Golden Green Inc.s holdings in Exact []

Related Stocks: IIVI , UPS , CLNE , EXAS , LMND , AI , BHP , INMD , MDB , BABA , TDOC , WMB , PSX , CLX , FVRR ,

Related Stocks: EXAS , BUD , GE , EMO ,

Related Stocks: ISEE , KOD , VRDN , INBX , ATXS , XENE , PRCT , ICVX , SLGC , HLTH , SMFR , IMRX , KDMN , MDT , DRNA , NARI , EXAS , XLRN ,

Related Stocks: EXAS , RNG , ZG , FTCH , GLBL , GLBL , ACEV , ATMR , APTMU , APMIU , HTPA , NXU , APO , ROT , STPC , CTAC , DEH , GLEO ,

Related Stocks: PTON , EXAS , ASND , VRM , AFRM , APP , SQ , CMG ,

Related Stocks: SPHB , NVDA , SYK , EXAS , PG ,

Shares of these genomics stocks have fallen far enough this year to attract some bargain shoppers.

Inotiv (NASDAQ:NOTV) and Exact Sciences (NASDAQ:EXAS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations and profitability. Profitability This table compares Inotiv and Exact Sciences net margins, return on equity and return on assets. []

Exact Sciences Corp's (NASDAQ: EXAS) Q3 revenues rose 12% Y/Y to $456.4 million, beating the consensus of $430.03 million. The increase is attributable to increased revenues from its screening and p

Exact Sciences Corporation (EXAS) CEO Kevin Conroy on Q3 2021 Results - Earnings Call Transcript

Exact Sciences (EXAS) delivered earnings and revenue surprises of -8.99% and 6.37%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?